RBC Bioscience Corporation (TPEX:6848)
Taiwan · Delayed Price · Currency is TWD 21.40
+0.10 (0.47%)
Oct 8, 2026, 11:53 AM CST
RBC Bioscience Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 305 | 241 | 248 | 210 | 206 | 459 | |
Market Cap Growth | 18.23% | -2.96% | 17.90% | 2.21% | -55.24% | - |
Enterprise Value | 651 | 616 | 632 | 617 | 596 | 946 |
Last Close Price | 21.40 | 13.87 | 14.05 | 11.32 | 10.37 | 22.44 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.55 | 10.22 | 11.49 | 32.69 | 54.44 | 15.99 |
PS Ratio | 1.38 | 1.10 | 1.21 | 1.22 | 1.18 | 1.83 |
PB Ratio | 1.17 | 0.90 | 0.99 | 0.87 | 0.83 | 1.79 |
P/TBV Ratio | 1.25 | 0.96 | 1.05 | 0.89 | 0.84 | 1.81 |
P/FCF Ratio | 7.28 | 7.06 | 4.61 | 25.59 | - | - |
P/OCF Ratio | 7.38 | 5.94 | 4.43 | 15.92 | 31.15 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.95 | 2.80 | 3.08 | 3.58 | 3.43 | 3.77 |
EV/EBITDA Ratio | 15.41 | 12.50 | 12.25 | 19.36 | 23.80 | 15.39 |
EV/EBIT Ratio | 24.33 | 17.59 | 17.86 | 42.42 | 76.89 | 19.47 |
EV/FCF Ratio | 15.52 | 18.08 | 11.75 | 75.08 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.50 | 1.46 | 1.82 | 1.96 | 1.94 | 1.99 |
Debt / EBITDA Ratio | 9.20 | 7.75 | 8.59 | 14.17 | 17.82 | 7.51 |
Debt / FCF Ratio | 9.27 | 11.48 | 8.45 | 57.42 | - | - |
Net Debt / Equity Ratio | 1.33 | 1.32 | 1.50 | 1.69 | 1.63 | 1.61 |
Net Debt / EBITDA Ratio | 8.42 | 7.20 | 7.26 | 12.76 | 16.21 | 6.73 |
Net Debt / FCF Ratio | 8.24 | 10.41 | 6.97 | 49.49 | -120.96 | -0.87 |
Asset Turnover | 0.30 | 0.30 | 0.27 | 0.22 | 0.21 | 0.37 |
Inventory Turnover | 2.42 | 2.36 | 2.21 | 2.17 | 2.05 | 2.40 |
Quick Ratio | 0.61 | 0.66 | 0.85 | 0.89 | 0.83 | 0.83 |
Current Ratio | 1.08 | 1.25 | 1.41 | 1.41 | 1.27 | 1.41 |
Return on Equity (ROE) | 8.09% | 9.09% | 8.80% | 2.63% | 1.49% | 13.31% |
Return on Assets (ROA) | 2.25% | 2.94% | 2.91% | 1.18% | 0.59% | 4.47% |
Return on Invested Capital (ROIC) | 3.52% | 4.44% | 4.45% | 1.82% | 0.90% | 9.23% |
Return on Capital Employed (ROCE) | 4.40% | 5.60% | 5.40% | 2.20% | 1.20% | 6.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.89% | 9.79% | 8.70% | 3.06% | 1.84% | 6.25% |
FCF Yield | 13.73% | 14.17% | 21.71% | 3.91% | -1.63% | -103.39% |
Dividend Yield | 16.52% | 10.82% | 3.98% | 3.54% | 9.82% | 3.68% |
Payout Ratio | 20.33% | 18.19% | 60.16% | 226.02% | 312.23% | 50.06% |
Buyback Yield / Dilution | -0.14% | -0.18% | -0.37% | 0.08% | -5.81% | -2.28% |
Total Shareholder Return | 16.37% | 10.64% | 3.62% | 3.61% | 4.01% | 1.41% |